#United States #Philadelphia #Securities Fraud #Berger Montague #Hims & Hers

Investors Alerted: Possible Securities Fraud Involving Hims & Hers Health Inc.

In a significant legal development, Berger Montague, a prominent national securities litigation law firm, is launching an investigation into potential securities fraud claims against Hims & Hers Health Inc. (NYSE: HIMS). This investigation could have substantial implications for investors who acquired Hims & Hers securities during a specified period earlier this year.

Background on the Investigation

The scope of the investigation is centered on Hims & Hers' business practices and their statements pertaining to the nature and regulatory status of their GLP-1 offerings, which are designed for weight management. Investors who purchased shares between April 29, 2025, and June 22, 2025, are particularly being urged to consider the ramifications of these allegations. The deadline for affected investors to seek representation is August 25, 2025, by which time they may apply to be appointed as lead plaintiffs.

The urgency surrounding this investigation was compounded when Novo Nordisk, a critical partner of Hims & Hers, publicly announced on June 23, 2025, that it was terminating its partnership with the company. This termination was based on claims that Hims & Hers had engaged in misleading marketing and sold unapproved compounded versions of a drug called semaglutide, prompting a remarkable drop of over 34% in the company's share prices during intraday trading.

Allegations and Potential Violations

Berger Montague’s investigation revolves around several alarming allegations. During the Class Period, it's been claimed that Hims & Hers provided materially false or misleading statements to investors while also omitting critical information regarding the regulatory compliance of their health products. Such actions, if proven true, could signify violations of federal securities laws.

In light of these developments, Hims & Hers investors are encouraged to engage further with Berger Montague to understand their legal rights and options. The firm continues to gather information to assess whether Hims & Hers and its executives directly misled investors and whether the public disclosure of their practices was sufficiently transparent.

How Affected Investors Can Proceed

If you are among those who invested in Hims & Hers during the specified Class Period and have concerns regarding these developments, it is crucial to act swiftly. Investors who wish to explore their rights or seek representation are advised to reach out directly to Berger Montague's attorneys.

• - Contact Andrew Abramowitz at [email protected] or call (215) 875-3015.
• - Contact Caitlin Adorni at [email protected] or call (267) 764-4865.

About Berger Montague

Founded in 1970, Berger Montague has built a robust reputation in securities class action litigation, representing both individual and institutional investors across the United States. With offices strategically located in major cities such as Philadelphia, Washington D.C., and San Francisco, the firm has a legacy of advocating for shareholders' rights and accountability in corporate governance. For over five decades, they have served as lead counsel in multiple groundbreaking lawsuits, making significant impacts in the realm of securities litigation and corporate practices.

Overall, this investigation presents a critical opportunity for investors to recover losses associated with alleged misleading practices. Stakeholders are encouraged to get informed and remain active in their response to these troubling allegations concerning Hims & Hers Health Inc.

Failure to act by the deadline of August 25, 2025, may result in a loss of potential recovery for affected investors, making timely action paramount. The legal landscape is watchful, and the coming months will likely reveal greater insights into this developing case.